UK Markets closed

Aerie Pharmaceuticals, Inc. (AERI)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
6.73-0.38 (-5.34%)
At close: 04:00PM EST
6.73 0.00 (0.00%)
After hours: 04:01PM EST

Aerie Pharmaceuticals, Inc.

4301 Emperor Boulevard
Suite 400
Durham, NC 27703
United States
919 237 5300

IndustryDrug Manufacturers—Specialty & Generic
Full-time employees365

Key executives

NameTitlePayExercisedYear born
Dr. Benjamin F. McGraw III, J.D., Pharm.D.Exec. Chairman92.5kN/A1949
Mr. Thomas A. MitroPres & COO747.68kN/A1958
Dr. Casey C. KopczynskiCo-Founder & Chief Scientific Officer665.58kN/A1961
Mr. John W. LaRocca Esq.Gen. Counsel & Sec.658.86kN/A1965
Dr. David A. Hollander M.B.A., M.D.Chief R&D Officer648.77kN/A1974
Mr. Raj KannanCEO & DirectorN/AN/A1963
Mr. Jeffrey CalabreseDirector of AccountingN/AN/AN/A
Ms. Ami BavishiDirector of Investor RelationsN/AN/AN/A
Ms. Carolyn McAuliffeSr. Director of CommunicationsN/AN/AN/A
Mr. Tad HeitmannVP of MarketingN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, ocular surface, and retinal diseases in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma. The company is also developing AR-15512 to treat signs and symptoms of dry eye; and AR-1105, AR-13503 SR, and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.

Corporate governance

Aerie Pharmaceuticals, Inc.’s ISS governance QualityScore as of 26 September 2021 is 9. The pillar scores are Audit: 6; Board: 6; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.